Metformin Hydrochloride Drug Combination Sitagliptin Phosphate

A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES.

Also Known As:

Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Janumet; Sitagliptin Phosphate Metformin Hydrochloride Drug Combination; Sitagliptin Phosphate-Metformin Hydrochloride Drug Combination

Networked: 8 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Arturi, Franco: 1 article (01/2017)
2.	Gallelli, Luca: 1 article (01/2017)
3.	Palleria, Caterina: 1 article (01/2017)
4.	Ruffo, Mariafrancesca: 1 article (01/2017)
5.	Serra, Raffaele: 1 article (01/2017)
6.	Succurro, Elena: 1 article (01/2017)
7.	Ricks, Janet: 1 article (01/2016)
8.	Sankoorikal, Vivek-Thomas J: 1 article (01/2016)
9.	Clements, Elizabeth: 1 article (12/2012)
10.	Miller, Shannon: 1 article (12/2012)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 10/01/2008 - "Janumet: a combination product suitable for use in patients with Type 2 diabetes." 11/01/2010 - "Janumet (50/850 mg or 50/1.000 mg), twice daily, is indicated in the treatment of type 2 diabetes and is currently reimbursed in Belgium after failure of metformin monotherapy or the prior demonstration of the efficacy of adding sitaglitptin (Januvia) to metformin." 07/30/2009 - "Janumet(TM,) a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 diabetes, that are inadequately controlled, either by sitagliptin or metformin alone or together in free-dose combination form. " 06/04/2007 - "Sitagliptin/metformin (Janumet) for type 2 diabetes." 01/01/2017 - "The fixed dose combination of sitagliptin 50 mg and metformin 850 mg (Janumet ®), is indicated for the treatment of type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control in patients treated with metformin alone. "
2.	Pancreatitis 01/01/2010 - "To date, 88 cases of acute pancreatitis have been reported to the FDA in patients taking sitagliptin (Januvia/Janumet). "
3.	Insulin Resistance 11/01/2010 - "Janumet is a fixed-dose combination of sitagliptin, a specific inhibitor of dipeptidylpeptidase-4 that blocks the rapid degradation of so-called incretin hormones (resulting in a potentiation of insulin secretion and reduction of glucagon secretion in a glucose-dependent manner), and of metformin, a biguanide compound that reduces glucose hepatic production and slightly improves insulin sensitivity. "
4.	Hyperglycemia 01/01/2016 - "He was evaluated at another clinic where he was prescribed sitagliptin/metformin (Janumet) for his uncontrolled hyperglycemia. "
5.	Diabetes Mellitus 12/01/2012 - "Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus."

Related Drugs and Biologics

1.	Sitagliptin Phosphate (Januvia)
2.	Metformin (Glucophage)
3.	Incretins
4.	Hormones (Hormone)
5.	Glucose (Dextrose)
6.	Glucagon (Glukagon)
7.	Biguanides

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control